| Ashley Gallup, | |
|
2817 Se 91st St, Moore, OK 73160-9123 | |
| (405) 371-5729 | |
| Not Available |
| Full Name | Ashley Gallup |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 8 Years |
| Location | 2817 Se 91st St, Moore, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407205347 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163WC0200X | Registered Nurse - Critical Care Medicine | R0101320 (Oklahoma) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 101320 (Oklahoma) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Digestive Disease Specialists Inc | 7315939279 | 45 |
News Archive
Whether or not Californians approve Proposition 19 on November 2, the proposition is the first of many to legalize marijuana for recreational use and turn it into an unregulated commercial enterprise.
Genentech, a member of the Roche Group, today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous (SC) formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous (IV) formulation every four weeks.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds significant trends in multiple epidemiological parameters to be driving the increase in drug-treatment opportunities for pancreatic cancer over the period 2009 to 2024, including population aging, increasing risk of recurrence following resection and modest improvements in survival.
Time spent in the drudgery of strenuous exercise is a well-documented turn-off for many people who want to get in better shape. In a new study, researchers show that exercisers can burn as many as 200 extra calories in as little as 2.5 minutes of concentrated effort a day—as long as they intersperse longer periods of easy recovery in a practice known as sprint interval training.
Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.
› Verified 1 days ago
| Entity Name | Board Of Regents Of The University Of Oklahoma - Ou Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801869250 PECOS PAC ID: 2860304334 Enrollment ID: O20031103000607 |
News Archive
Whether or not Californians approve Proposition 19 on November 2, the proposition is the first of many to legalize marijuana for recreational use and turn it into an unregulated commercial enterprise.
Genentech, a member of the Roche Group, today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous (SC) formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous (IV) formulation every four weeks.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds significant trends in multiple epidemiological parameters to be driving the increase in drug-treatment opportunities for pancreatic cancer over the period 2009 to 2024, including population aging, increasing risk of recurrence following resection and modest improvements in survival.
Time spent in the drudgery of strenuous exercise is a well-documented turn-off for many people who want to get in better shape. In a new study, researchers show that exercisers can burn as many as 200 extra calories in as little as 2.5 minutes of concentrated effort a day—as long as they intersperse longer periods of easy recovery in a practice known as sprint interval training.
Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.
› Verified 1 days ago
| Entity Name | Digestive Disease Specialists Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366489213 PECOS PAC ID: 7315939279 Enrollment ID: O20040331001151 |
News Archive
Whether or not Californians approve Proposition 19 on November 2, the proposition is the first of many to legalize marijuana for recreational use and turn it into an unregulated commercial enterprise.
Genentech, a member of the Roche Group, today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous (SC) formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous (IV) formulation every four weeks.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds significant trends in multiple epidemiological parameters to be driving the increase in drug-treatment opportunities for pancreatic cancer over the period 2009 to 2024, including population aging, increasing risk of recurrence following resection and modest improvements in survival.
Time spent in the drudgery of strenuous exercise is a well-documented turn-off for many people who want to get in better shape. In a new study, researchers show that exercisers can burn as many as 200 extra calories in as little as 2.5 minutes of concentrated effort a day—as long as they intersperse longer periods of easy recovery in a practice known as sprint interval training.
Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.
› Verified 1 days ago
| Entity Name | Ou Health Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528642642 PECOS PAC ID: 5991105876 Enrollment ID: O20210615000618 |
News Archive
Whether or not Californians approve Proposition 19 on November 2, the proposition is the first of many to legalize marijuana for recreational use and turn it into an unregulated commercial enterprise.
Genentech, a member of the Roche Group, today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous (SC) formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous (IV) formulation every four weeks.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds significant trends in multiple epidemiological parameters to be driving the increase in drug-treatment opportunities for pancreatic cancer over the period 2009 to 2024, including population aging, increasing risk of recurrence following resection and modest improvements in survival.
Time spent in the drudgery of strenuous exercise is a well-documented turn-off for many people who want to get in better shape. In a new study, researchers show that exercisers can burn as many as 200 extra calories in as little as 2.5 minutes of concentrated effort a day—as long as they intersperse longer periods of easy recovery in a practice known as sprint interval training.
Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ashley Gallup, 2817 Se 91st St, Moore, OK 73160-9123 Ph: (405) 371-5729 | Ashley Gallup, 2817 Se 91st St, Moore, OK 73160-9123 Ph: (405) 371-5729 |
News Archive
Whether or not Californians approve Proposition 19 on November 2, the proposition is the first of many to legalize marijuana for recreational use and turn it into an unregulated commercial enterprise.
Genentech, a member of the Roche Group, today announced that the SUMMACTA study met its primary endpoint, showing comparable efficacy (non-inferiority) of the subcutaneous (SC) formulation of ACTEMRA (tocilizumab) 162mg weekly compared to 8 mg/kg ACTEMRA intravenous (IV) formulation every four weeks.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds significant trends in multiple epidemiological parameters to be driving the increase in drug-treatment opportunities for pancreatic cancer over the period 2009 to 2024, including population aging, increasing risk of recurrence following resection and modest improvements in survival.
Time spent in the drudgery of strenuous exercise is a well-documented turn-off for many people who want to get in better shape. In a new study, researchers show that exercisers can burn as many as 200 extra calories in as little as 2.5 minutes of concentrated effort a day—as long as they intersperse longer periods of easy recovery in a practice known as sprint interval training.
Eisai Inc. and Morphotek®, Inc. announced today that the Medical Ethical Review Committee and Central Committee on Research Involving Human Subjects of the Netherlands cleared its Clinical Trial Application to test the investigational new drug MORAb-022 in a Phase I clinical trial that will include both normal healthy volunteers and subjects diagnosed with rheumatoid arthritis.
› Verified 1 days ago